Simulations Plus to acquire DILIsym for up to $10M
May 02, 2017
Decision Analysis | Research Triangle Park, NC | Corporate Acquisition
Simulations Plus (NASDAQ: SLP), a provider of simulation and modeling software used in pharmaceutical discovery and development, has agreed to acquire DILIsym Services for $5 million up front, plus an earn-out of up to $5 million more over the next three years. DILIsym sells software simulating drug-induced liver injuries and provides related consulting services. Simulations Plus stock closed up more than 3% on Monday.